| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA35650
Max Phase: Preclinical
Molecular Formula: C22H46N6O9
Molecular Weight: 538.64
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCN(CC)CC1OC(OC2C(N)CC(N)C(OC3OC(CN)C(O)C(O)C3N)C2O)C(O)C(N)C1O
Standard InChI: InChI=1S/C22H46N6O9/c1-3-28(4-2)7-11-14(29)12(26)17(32)22(35-11)37-20-9(25)5-8(24)19(18(20)33)36-21-13(27)16(31)15(30)10(6-23)34-21/h8-22,29-33H,3-7,23-27H2,1-2H3
Standard InChI Key: XJLZMLDGQGFSSX-UHFFFAOYSA-N
Associated Targets(non-human)
Lysosomal phospholipase A1 40 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 538.64 | Molecular Weight (Monoisotopic): 538.3326 | AlogP: -5.98 | #Rotatable Bonds: 9 |
| Polar Surface Area: 271.41 | Molecular Species: BASE | HBA: 15 | HBD: 10 |
| #RO5 Violations: 3 | HBA (Lipinski): 15 | HBD (Lipinski): 15 | #RO5 Violations (Lipinski): 3 |
| CX Acidic pKa: 12.40 | CX Basic pKa: 9.54 | CX LogP: -5.75 | CX LogD: -13.36 |
| Aromatic Rings: 0 | Heavy Atoms: 37 | QED Weighted: 0.13 | Np Likeness Score: 0.86 |
References
| 1. Mingeot-Leclercq MP, Van Schepdael A, Brasseur R, Busson R, Vanderhaeghe HJ, Claes PJ, Tulkens PM.. (1991) New derivatives of kanamycin B obtained by modifications and substitutions in position 6''. 2. In vitro and computer-aided toxicological evaluation with respect to interactions with phosphatidylinositol., 34 (4): [PMID:2016725] [10.1021/jm00108a036] |
Source
Source(1):